Leznoda (Brinzolamide, Brimonidine Tartrate)

Brinzolamide belongs to the carbonic anhydrase inhibitor class. It blocks the enzyme carbonic anhydrase in the ciliary body of the eye, which reduces the production of aqueous humor. The resulting decrease in fluid volume lowers intra‑ocular pressure, contributing to glaucoma control.

The dosing regimen for Leznoda is determined by the prescribing ophthalmologist based on the patient’s condition and response. Typically, the product is administered as one or two drops per eye at prescribed intervals, but the exact schedule should always follow the clinician’s instructions.

Safety data for Leznoda in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss individual risks and consider alternative therapies if appropriate.

To order Leznoda, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Leznoda combines two mechanisms—carbonic anhydrase inhibition and alpha‑2 adrenergic agonism—offering a broader IOP‑lowering effect than single‑agent drops such as timolol or latanoprost alone. This dual action can improve control in patients who need additional pressure reduction without adding separate medications.

Leznoda should be stored at room temperature, away from direct sunlight and moisture. Keep the bottle tightly closed when not in use and retain it in the original packaging. Do not freeze the product, and discard any solution that appears discolored or contains particles.

Leznoda is applied topically to the eye. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place the prescribed number of drops into the conjunctival sac. Close the eye gently for a few seconds, avoid blinking excessively, and wait at least five minutes before using another eye medication.

Serious adverse events, though rare, include severe allergic reactions such as angio‑edema or anaphylaxis, acute angle‑closure glaucoma triggered by improper use, and significant systemic hypotension or bradycardia from the brimonidine component. Patients should seek immediate medical attention if they experience these symptoms.

Leznoda is contraindicated in patients with known hypersensitivity to brinzolamide, brimonidine, or any excipients in the formulation. It should also be avoided in individuals with severe cardiovascular disease, uncontrolled hypotension, or those who have experienced acute angle‑closure glaucoma without proper medical supervision.